Clinical Update on Pentoxifylline Therapy for Diabetes-Induced Peripheral Vascular Disease

Abstract

Spanish

French

OBJECTIVE:

To introduce readers to the use of pentoxifylline for diabetes-induced peripheral vascular disease. The article provides background on the pathophysiology of diabetic foot ulcers as well as a review of the literature on the therapeutic use of pentoxifylline for treating this disorder.

DATA SOURCES:

A MEDLINE search was used to identify pertinent literature, including review articles and case reports. Key index terms included pentoxifylline, diabetic foot ulcer, neuropathy, peripheral vascular disease, and intermittent claudication

DATA EXTRACTION:

Basic pharmacologic data regarding absorption, distribution, metabolism, and excretion were reported in normal subjects as well as in patients with renal impairment. Open and controlled clinical trials also were analyzed; subjective symptoms were reported. The economic implications also were reported. The pharmacist's role in patient education is discussed.

DATA SYNTHESIS:

Pentoxifylline 800 mg/d was found to be effective in improving the symptoms in patients with noninsulin-dependent diabetes mellitus, including improvement in walking distance, paresthesia, skin temperature, and subjective overall response. In nondiabetic patients, statistically significant differences in leg-ulcer healing were found between the treatment and placebo groups. Case reports illustrated healing times, which ranged from two weeks to six months. Pentoxifylline use in both insulin-dependent and noninsulin-dependent patients was assessed in clinical trials, with improvement of symptoms in both patient types.

CONCLUSIONS:

Studies show that pentoxifylline is an alternative to vascular surgery in the management of peripheral vascular disease in diabetic patients, particularly in those with chronic ulceration of the lower extremities that does not heal despite other optimal treatment regimens, including cessation of smoking, maintenance of normoglycemia, elimination of vasoconstrictive drugs, correctly fitted shoes, and appropriate wound care. Pentoxifylline therapy may provide an appropriate, economical treatment modality by reducing the need for hospitalization and vascular surgery.

Get full access to this article

View all access options for this article.

References

Foster

. Diabetes mellitus. In: Wilson

Braunwald

Isselbacher

Petersdorf

Martin

Fauci

, eds. Principles of internal medicine. 12th ed. New York: McGraw-Hill, 1991;1739.

Boulton

AJM

. The diabetic foot. Med Clin North Am 1988; 72:1513–30.

Kilo

. Peripheral vascular disease in diabetes. Hosp Med 1989; 25:3–14.

Ely

. Pentoxifylline therapy in dermatology: A review of localized hyperviscosity and its effects on the skin. Dermatol Clin 1988; 6:585–604.

Levin

. The diabetic foot: Pathophysiology, evaluation, and treatment. In: Levin

O'Neal

, eds. The diabetic foot. St. Louis: CV Mosby, 1988:1–50.

Kannel

. Cigarette smoking and peripheral arterial disease. Prim Cardiol 1986; 12:13–8.

Dukes

MNG

, ed: Meyler's side effects of drugs. Amsterdam: Elsevier, 1988: 267–73, 409.

Bays

Pfeifer

. Peripheral diabetic neuropathy. Med Clin North Am 1988; 72:1439–64.

Sargent

. Hemorrheology. In: Levin

O'Neal

, eds. The diabetic foot. St. Louis: CV Mosby, 1988:71–5.

10.

Ward

Clissold

. Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34:50–97.

11.

Perego

Sergio

Artale

Giunti

Danese

. Haemorrheological improvement by pentoxifylline in patients with peripheral arterial occlusive disease. Curr Med Res Opin 1986; 10:135–8.

12.

Poggesi

Scarti

Boddi

Masotti

Serneri

. Pentoxifylline treatment in patients with occlusive peripheral arterial disease: Circulatory changes and effects on prostaglandin synthesis. Angiology 1985; 36:628–37.

13.

Beerman

Ings

Mansby

Chamberlain

McDonald

. Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther 1985; 37:25–8.

14.

Wills

Waller

Puri

Yakatan

. Influence of food on the bioavailability of Trental (pentoxifylline) in man. Drug Dev Ind Pharm 1981; 7:385–96.

15.

Crowder

Cohn

Savitsky

Morgan

Slywka

Cobert

. Efficacy and safety of pentoxifylline in geriatric patients with intermittent claudication. Angiology 1989; 40:795–802.

16.

Baker

Campbell

. Pentoxifylline: A new agent for intermittent claudication. Drug Intell Clin Pharm 1985; 19:345–8.

17.

Dettelbach

Aviado

. Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication. J Clin Pharmacol 1985; 25:8–26.

18.

Hartshorn

Deans

. Pharmacologic treatment of intermittent claudication with special emphasis on pentoxifylline. J Cardiovasc Nurs 1987; 1 (2):65–8.

19.

Aviado

Porter

. Pentoxifylline: A new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 1984; 4:297–307.

20.

Angelkort

Spürk

Habbaba

Mahder

. Blood flow properties and walking performance in chronic arterial occlusive disease. Angiology 1985; 36:285–92.

21.

Johnson

Sentissi

Baldwin

Hamilton

Dion

. Treatment of claudication with pentoxifylline: Are benefits related to improvement in viscosity?. J Vasc Surg 1987; 6:211–6.

22.

Reich

Gillings

. Effects of pentoxifylline on severe intermittent claudication. Angiology 1987; 38:651–6.

23.

Kellner

. Treatment of chronic arterial circulatory disorders: A double-blind trial with pentoxifylline (Trental 400). Pharmatherapeutica 1983; 3(suppl l):67–73.

24.

Schwartz

Witte

. Cost-effectiveness of pentoxifylline in the treatment of intermittent claudication of peripheral arterial disease. Today's Ther Trends 1990; 7 (4):29–36.

25.

Barbarino

. Pentoxifylline in the treatment of venous leg ulcers. Curr Med Res Opin 1992; 12:547–51.

26.

Ehrly

. Clinical implications of altered flexibility of erythrocytes in patients with intermittent claudication. Vasc Med 1983; 1:175–80.

27.

Ehrly

Saeger-Lorenz

. Influence of pentoxifylline on muscle tissue oxygen tension (pO₂) of patients with intermittent claudication before and after pedal ergometer exercise. Angiology 1987; 38:93–100.

28.

Schubotz

. Double-blind trial of pentoxifylline in diabetes with peripheral vascular disorders. Pharmatherapeutica 1976; 1:172–9.

29.

Ferrari

Fioravanti

Patti

Viola

Solerte

. Effects of long-term treatment (4 years) with pentoxifylline on haemorrheological changes and vascular complications in diabetic patients. Pharmatherapeutica 1987; 5:26–39.

30.

Colgan

Dormandy

Jones

Schraibman

Shanik

Young

RAL

. Oxpentifylline treatment of venous ulcers of the leg. Br Med J 1990; 300:972–4.

31.

Weitgasser

. The use of pentoxifylline (Trental 400) in the treatment of leg ulcers: Results of a double-blind trial. Pharmatherapeutica 1983; 3(suppl 1): 143–51.

32.

Adler

. Assessing the effects of pentoxifylline (Trental) on diabetic neurotrophic foot ulcers. J Foot Surg 1991; 30:300–3.

33.

Schwartz

Logan

Johnson

Stroedel

Fine

Kazmers

. Pentoxifylline increases extremity blood flow in diabetic atherosclerosis patients. Arch Surg 1989; 124:434–7.

34.

Pierce

Crowhurst

Caneva

. Pentoxifylline: A new drug review and case report. J Am Podiatr Med Assoc 1986; 76:407–40.

35.

Brenner

. Nonhealing venous stasis ulcers: Pentoxifylline as adjunctive therapy. J Am Podiatr Med Assoc 1987; 77:586–8.

36.

Cohen

Harris

. Pentoxifylline and diabetic neuropathy (letter). Ann Intern Med 1987; 107:600–1.

37.

Sternitzkv

Seige

. Clinical investigation of the effects of pentoxifylline in patients with severe peripheral occlusive vascular disease. Curr Med Res Opin 1985; 9:602–10.

38.

Campbell

. A professional update for pharmacists: Diabetes and peripheral arterial disease. An accredited continuing education program (ACPE no. 680 313-91-011). Somerville, NJ: Hoechst-Roussel, 1991.